79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study. (December 2022)

Record Type:
Journal Article
Title:
79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study. (December 2022)
Main Title:
79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
Authors:
Wu, X.
Xia, L.
Wang, J.
Wang, C.
Zhang, Q.
Zhu, J.
Rao, Q.
Cheng, H.
Liu, Z.
Y. Yin,
Ai, X.
Gulina, K.
Zheng, H.
Luo, X.
Chang, B.
Li, L.
Liu, H.
Li, Y.
Zhu, J.
Abstract:
Is Part Of:
Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Issue Display:
Volume 16, Issue 1 (2022)
Year:
2022
Volume:
16
Issue:
1
Issue Sort Value:
2022-0016-0001-0000
Page Start:
Page End:
Publication Date:
2022-12
Subjects:
Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:
https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:
10.1016/j.iotech.2022.100183 ↗
Languages:
English
ISSNs:
2590-0188
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
24685.xml